• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）人类感染对照模型：伦理、挑战病原体生产及监管问题

SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues.

作者信息

Baay Marc, Neels Pieter

机构信息

P95 Epidemiology & Pharmacovigilance, Leuven, Belgium.

International Alliance for Biological Standardization - IABS, Geneva, Switzerland.

出版信息

Biologicals. 2020 Sep;67:69-74. doi: 10.1016/j.biologicals.2020.08.006. Epub 2020 Aug 15.

DOI:10.1016/j.biologicals.2020.08.006
PMID:32829985
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7428779/
Abstract

This second International Alliance for Biological Standardization COVID-19 webinar brought together a broad range of international stakeholders, including academia, regulators, funders and industry, with a considerable participation from low- and middle-income countries, to discuss the use of controlled human infection models to accelerate development and market authorization assessment of a vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

摘要

第二届国际生物标准化联盟新冠病毒网络研讨会汇聚了众多国际利益相关者，包括学术界、监管机构、资助者和行业代表，低收入和中等收入国家也有大量人员参与，共同探讨如何利用人类感染对照模型来加速针对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的研发及上市许可评估。

相似文献

1
SARS-CoV-2 controlled human infection models: Ethics, challenge agent production and regulatory issues.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）人类感染对照模型：伦理、挑战病原体生产及监管问题
Biologicals. 2020 Sep;67:69-74. doi: 10.1016/j.biologicals.2020.08.006. Epub 2020 Aug 15.
2
SARS-CoV-2: Virology, epidemiology, immunology and vaccine development.严重急性呼吸综合征冠状病毒2：病毒学、流行病学、免疫学与疫苗研发
Biologicals. 2020 Jul;66:35-40. doi: 10.1016/j.biologicals.2020.06.005. Epub 2020 Jun 23.
3
Accelerating Development of SARS-CoV-2 Vaccines - The Role for Controlled Human Infection Models.加速严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗的研发——人体感染控制模型的作用
N Engl J Med. 2020 Sep 3;383(10):e63. doi: 10.1056/NEJMp2020076. Epub 2020 Jul 1.
4
Covid-19 vaccines: Should we allow human challenge studies to infect healthy volunteers with SARS-CoV-2?新冠疫苗：我们应该允许人体挑战研究让健康志愿者感染新冠病毒吗？
BMJ. 2020 Nov 9;371:m4258. doi: 10.1136/bmj.m4258.
5
COVID-19 human challenge studies: ethical issues.COVID-19 人体挑战研究：伦理问题。
Lancet Infect Dis. 2020 Aug;20(8):e198-e203. doi: 10.1016/S1473-3099(20)30438-2. Epub 2020 May 29.
6
Ethics of controlled human infection to address COVID-19.用于应对新冠疫情的人体感染对照试验伦理问题。
Science. 2020 May 22;368(6493):832-834. doi: 10.1126/science.abc1076. Epub 2020 May 7.
7
Covid-19: Human challenge studies will see people purposefully infected with virus.新冠疫情：人体挑战试验将让人们故意感染病毒。
BMJ. 2020 Oct 22;371:m4101. doi: 10.1136/bmj.m4101.
8
Progress and Challenges in the Development of COVID-19 Vaccines and Current Understanding of SARS-CoV-2- Specific Immune Responses.COVID-19 疫苗研发的进展与挑战及对 SARS-CoV-2 特异性免疫应答的现有认识。
J Microbiol Biotechnol. 2020 Aug 28;30(8):1109-1115. doi: 10.4014/jmb.2006.06006.
9
COVID-19 and Moral Imperialism in Multinational Clinical Research.新冠疫情与跨国临床研究中的道德帝国主义。
Arch Med Res. 2020 Aug;51(6):572-573. doi: 10.1016/j.arcmed.2020.04.017. Epub 2020 Apr 29.
10
SARS-CoV-2 Vaccines: Status Report.SARS-CoV-2 疫苗：现状报告。
Immunity. 2020 Apr 14;52(4):583-589. doi: 10.1016/j.immuni.2020.03.007. Epub 2020 Apr 6.

引用本文的文献

1
Fourth Controlled Human Infection Model (CHIM) meeting, CHIM regulatory issues, May 24, 2023.第四次人工感染控制模型（CHIM）会议，CHIM 监管问题，2023 年 5 月 24 日。
Biologicals. 2024 Feb;85:101745. doi: 10.1016/j.biologicals.2024.101745. Epub 2024 Feb 10.
2
Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.人类和动物模型中与疫苗相关的增强疾病：疫苗开发的经验与挑战
Front Microbiol. 2022 Aug 10;13:932408. doi: 10.3389/fmicb.2022.932408. eCollection 2022.
3
Controlled Human Infection Models To Accelerate Vaccine Development.控制人体感染模型以加速疫苗开发。
Clin Microbiol Rev. 2022 Sep 21;35(3):e0000821. doi: 10.1128/cmr.00008-21. Epub 2022 Jul 6.
4
Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults.在年轻成年人中进行 SARS-CoV-2 人体挑战的安全性、耐受性和病毒动力学。
Nat Med. 2022 May;28(5):1031-1041. doi: 10.1038/s41591-022-01780-9. Epub 2022 Mar 31.
5
Public attitudes to a human challenge study with SARS-CoV-2: a mixed-methods study.公众对新型冠状病毒（SARS-CoV-2）人体挑战研究的态度：一项混合方法研究。
Wellcome Open Res. 2022 Feb 10;7:49. doi: 10.12688/wellcomeopenres.17516.1. eCollection 2022.
6
Vaccines against leishmaniasis: using controlled human infection models to accelerate development.利什曼病疫苗：利用人体感染控制模型加速开发。
Expert Rev Vaccines. 2021 Nov;20(11):1407-1418. doi: 10.1080/14760584.2021.1991795. Epub 2021 Oct 27.
7
Controlled Human Infection to Speed Up SARS-CoV-2 Vaccine Development.通过可控人体感染加速新型冠状病毒疫苗研发
Front Immunol. 2021 Mar 12;12:658783. doi: 10.3389/fimmu.2021.658783. eCollection 2021.
8
Human Challenge Studies With Wild-Type Severe Acute Respiratory Sydrome Coronavirus 2 Violate Longstanding Codes of Human Subjects Research.针对野生型严重急性呼吸综合征冠状病毒2的人体激发试验违反了长期以来的人体研究规范。
Open Forum Infect Dis. 2020 Dec 28;8(1):ofaa615. doi: 10.1093/ofid/ofaa615. eCollection 2021 Jan.
9
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2.什么是有效的 COVID-19 疫苗？评估针对 SARS-CoV-2 的疫苗临床疗效的挑战综述。
Lancet Infect Dis. 2021 Feb;21(2):e26-e35. doi: 10.1016/S1473-3099(20)30773-8. Epub 2020 Oct 27.
10
Vaccines for COVID-19.COVID-19 疫苗。
Clin Exp Immunol. 2020 Nov;202(2):162-192. doi: 10.1111/cei.13517. Epub 2020 Oct 18.

本文引用的文献

1
Key criteria for the ethical acceptability of COVID-19 human challenge studies: Report of a WHO Working Group.COVID-19 人体挑战研究的伦理可接受性的关键标准：世卫组织工作组的报告。
Vaccine. 2021 Jan 22;39(4):633-640. doi: 10.1016/j.vaccine.2020.10.075. Epub 2020 Oct 28.
2
SARS-CoV-2: Virology, epidemiology, immunology and vaccine development.严重急性呼吸综合征冠状病毒2：病毒学、流行病学、免疫学与疫苗研发
Biologicals. 2020 Jul;66:35-40. doi: 10.1016/j.biologicals.2020.06.005. Epub 2020 Jun 23.
3
Genomewide Association Study of Severe Covid-19 with Respiratory Failure.全基因组关联研究严重新冠肺炎伴呼吸衰竭。
N Engl J Med. 2020 Oct 15;383(16):1522-1534. doi: 10.1056/NEJMoa2020283. Epub 2020 Jun 17.
4
COVID-19 human challenge studies: ethical issues.COVID-19 人体挑战研究：伦理问题。
Lancet Infect Dis. 2020 Aug;20(8):e198-e203. doi: 10.1016/S1473-3099(20)30438-2. Epub 2020 May 29.
5
Human challenge trial workshop: Focus on quality requirements for challenge agents, Langen, Germany, October 22, 2019.人类挑战试验研讨会：关注挑战剂的质量要求，德国兰根，2019 年 10 月 22 日。
Biologicals. 2020 Jul;66:53-61. doi: 10.1016/j.biologicals.2020.04.005. Epub 2020 May 4.
6
Ethics of controlled human infection to address COVID-19.用于应对新冠疫情的人体感染对照试验伦理问题。
Science. 2020 May 22;368(6493):832-834. doi: 10.1126/science.abc1076. Epub 2020 May 7.
7
Developing Covid-19 Vaccines at Pandemic Speed.以大流行速度研发新冠疫苗。
N Engl J Med. 2020 May 21;382(21):1969-1973. doi: 10.1056/NEJMp2005630. Epub 2020 Mar 30.
8
Genetic drift of human coronavirus OC43 spike gene during adaptive evolution.人类冠状病毒OC43刺突基因在适应性进化过程中的遗传漂变
Sci Rep. 2015 Jun 22;5:11451. doi: 10.1038/srep11451.